Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Parathyroid hormone-related protein 1-36 is one of several authentic secretory forms of PTHrP. It mimics the actions of parathyroid hormone (PTH) due to structural homology and ability to bind to and signal via the PTH/PTHrP receptor in bone and kidney. PTHrP 1-36 is equipotent to PTH 1-34, binding to the PTH/PTHrP receptor with equal affinity and activating the same intracellular signaling pathways with similar efficacy. The peptide has multiple biological effects including: - Reducing serum phosphorus and renal phosphorus threshold - Increasing fractional calcium excretion and nephrogenous cAMP excretion - Increasing plasma 1,25-dihydroxyvitamin D - Enhancing beta cell function and proliferation in pancreatic islets - Acting as an anabolic skeletal agent with potential for treating osteoporosis PTHrP 1-36 was first identified as the PTH-like hypercalcemic factor responsible for most cases of humoral hypercalcemia of malignancy (HHM).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on parathyroid hormone-related protein 1-36.